Clinical trial
A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 With Single-Ascending Doses in Healthy Participants and Multiple-Ascending Doses and Proof-of-Concept in Participants With Cystic Fibrosis
NCT06237335 is registered in ClinicalTrials.gov with ReCode Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 With Single-Ascending Doses in Healthy Participants and Multiple-Ascending Doses and Proof-of-Concept in Participants With Cystic Fibrosis
- Lead sponsor
- ReCode Therapeutics
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 1, 2024
- Completion date
- November 30, 2026
- Enrollment
- 128 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.